v3.25.2
Commercial Services and Loan Agreements with Eversana - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Feb. 01, 2022
Jan. 21, 2020
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Jan. 31, 2020
Commercial Services And Loan Agreements [Line Items]              
Selling, general and administrative     $ 5,134,902 $ 3,733,450 $ 9,432,407 $ 6,872,986  
Eversana Agreement [Member]              
Commercial Services And Loan Agreements [Line Items]              
Unreimbursed commercialization cost     79,800,000   $ 79,800,000    
Agreement expiration date Dec. 31, 2026            
Agreement term         On February 1, 2022, the Eversana Agreement was amended to extend the term from June 19, 2025 (five years from the date the Food & Drug Administration approved the Gimoti new drug application) to December 31, 2026, unless terminated earlier pursuant to its terms (the “Eversana Amendment”).    
Selling, general and administrative     $ 3,200,000 $ 2,200,000 $ 5,800,000 $ 3,600,000  
Eversana Agreement [Member] | Revolving Credit Facility [Member]              
Commercial Services And Loan Agreements [Line Items]              
Line of credit   $ 5,000,000          
Line of credit facility, Interest rate   10.00%          
Borrowings             $ 5,000,000
Eversana Agreement [Member] | Gimoti [Member] | Minimum [Member]              
Commercial Services And Loan Agreements [Line Items]              
Percentage of Product Profits   80.00%